Stock Yards Bank & Trust Co. increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 4.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 49,859 shares of the biopharmaceutical company’s stock after purchasing an additional 2,139 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $3,096,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of BMY. New Jersey Better Educational Savings Trust raised its stake in Bristol-Myers Squibb by 9.1% during the 3rd quarter. New Jersey Better Educational Savings Trust now owns 12,000 shares of the biopharmaceutical company’s stock valued at $745,000 after acquiring an additional 1,000 shares during the last quarter. Polianta Ltd purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $1,285,000. Private Capital Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $452,000. Selective Wealth Management purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $184,000. Finally, Bank of Montreal Can raised its stake in shares of Bristol-Myers Squibb by 13.9% during the 3rd quarter. Bank of Montreal Can now owns 5,862,162 shares of the biopharmaceutical company’s stock worth $363,924,000 after buying an additional 717,503 shares in the last quarter. 72.54% of the stock is owned by institutional investors and hedge funds.
Shares of BMY opened at $51.35 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. The firm has a market capitalization of $82.74 billion, a P/E ratio of 17.06, a PEG ratio of 1.41 and a beta of 1.08. Bristol-Myers Squibb Co has a twelve month low of $46.94 and a twelve month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Equities research analysts expect that Bristol-Myers Squibb Co will post 3.87 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.12%. The ex-dividend date of this dividend was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.
BMY has been the topic of a number of research reports. Morgan Stanley set a $59.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Tuesday. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $57.00 to $54.00 and set a “market perform” rating on the stock in a report on Tuesday, October 23rd. Wolfe Research started coverage on Bristol-Myers Squibb in a report on Tuesday, October 23rd. They issued an “outperform” rating and a $66.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Finally, Citigroup cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the company from $62.00 to $57.00 in a report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $62.48.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.